Use of a dopamine aganist in fibromyalgia: Where is the evidence?

Journal of Clinical Rheumatology

Volumn 9, Issue 4, 2003, Pages 211-214

  Yunus, Muhammad B ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; ROPINIROLE;

ADD ON THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; FIBROMYALGIA; HUMAN; NERVE EXCITABILITY; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME;

EID: 0041571893     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000081263.61307.f0     Document Type: Editorial

References (21)

1. Holman AJ. Ropinirole, open, preliminary observations of a dopamine agonist for refractory fibromyalgia. J Clin Rheumatol, 2003;9:277-279.
2. Scrabanek P, McCormick J. Follies and Fallacies in Medicine. Buffalo, NY: Prometheus Books, 1990.
3. Yunus MB, Aldag JC. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ. 1996;312:1339.
4. Yunus MB. Central sensitivity syndromes:a unified concept for fibromyalgia and other similar maladies. J Indian Rheum Assoc. 2000;8:27-33.
5. Yunus MB, Inanici F. Clinical characteristics and biopathophysiological mechanisms of fibromyalgia syndrome. In: Baldry PE (ed.), Myofascial Pain and Fibromyalgia Syndromes. New York: Churchill Livingstone, 2001;351-377.
6. Montplaisir J, Godbout R, Poirier G, et al. Restless legs syndrome and periodic limb movement disorder in sleep: pathophysiology and treatment with L-dopa. Clin Neuropharmacol. 1986;9:456-463.
7. Von Scheele C. Levodopa in restless legs. Lancet. 1986;2:426-427.
8. Russell IJ. Advances in fibromyalgia: possible role for neurochemicals. Am J Med Sci. 1998;377-384.
9. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355-474.
10. Formenti A, Martina M, Plebani A, et al. Multiple modulatory effects of dopamine on calcium channel kinetics in adult rat sensory system. J Physiol. 1998;509:395-409.
11. Gao X, Zhang YQ, Wu GC. Effects of dopaminergic agents on carrageenan hyperalgesia in rats. Eur J Pharmacol. 2000;406:53-58.
12. Gilbert AK, Franklin KB. Characterization of the analgesic properties of nomifensine in rats. Pharmacol Biochem Behav. 2001;68:783-787.
13. 2 receptors in the dorsolateral striatum. Brain Res. 2000;855:260-266.
14. Ciliax BJ, Nash N, Heilman C, et al. Dopamine D5 receptor immunolocalization in rat and monkey brain. Synapse. 2000;37:125-145.
15. Kitahama K, Nagatsu I, Geffard M, et al. Distribution of dopamine-immunoreactive fibers in the rat brainstem. J Chem Neuroanat. 2000;18:1-9.
16. Hagelberg N, Martikainen IK, Mansikka H, et al. Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity. Pain. 99:273-279.
17. Brodeur C, Montplaisir J, Godbout R, et al. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa. Neurology. 1988;38:1845-1848.
18. Trenkwalder C, Stiasny K, Pollmaeeher T, et al. L-dopa therapy of uraemic and idiopathic restless legs syndrome:a double-blind crossover trial. Sleep. 1995;118:681-618.
19. Ertas M, Sagduyu A, Arac N, et al. Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. Pain 1998;75:257-259.
20. Russell IJ, Vaeroy H, Javors M, et al. Cerebrospinal fluid bigenic amine metabolites in primary fibromyalgia syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;5:550-556.
21. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Herdman JG, Limbird LE (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001;549-567.